Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 13/20 | 0.48 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18861466 | 0.91 | GLS (0.49) | GLSSMN1; SMN2HRH3GSK3BCTPS1 | |
| SCHEMBL18861596 | 0.89 | GLS (0.51) | GLSSMN1; SMN2HRH3 | |
| SCHEMBL18861484 | 0.88 | GLS (0.48) | GLSKIF18AHRH3CCNE1CDK2 | |
| SCHEMBL18861483 | 0.88 | GLS (0.47) | GLSSMN1; SMN2HRH3CCNE1CDK2 | |
| SCHEMBL18861544 | 0.88 | GLS (0.47) | GLSSMN1; SMN2HRH3CCNE1CDK2 | |
| SCHEMBL18861609 | 0.84 | GLS (0.44) | GLSSMN1; SMN2 | |
| SCHEMBL18861608 | 0.84 | GLS (0.46) | GLSSMN1; SMN2HRH3CCNE1CDK2 | |
| SCHEMBL18860893 | 0.84 | GLS (0.56) | GLSHRH3 | |
| SCHEMBL18861600 | 0.84 | GLS (0.42) | GLSHRH3CCNE1CDK2GSK3B | |
| SCHEMBL18861454 | 0.81 | GLS (0.55) | GLSSMN1; SMN2CCNE1CDK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000479-B2 | Compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170137414-A1 | COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137414-A1 | COMPOUNDS AND THEIR METHODS OF USE | GLS, GLS2, GLUL | GLS 1/4885KIF18A 2342/4885SMN1; SMN2 3566/4885 |
| US-10000479-B2 | Compounds and their methods of use | GLS, GLS2, GLUL | GLS 1/4885KIF18A 2342/4885SMN1; SMN2 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.